About Neothetics (NASDAQ:NEOT)
Neothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. LIPO-202 is a first-in-class injectable formulation of the long-acting Beta2-adrenergic receptor agonist, and salmeterol xinafoate, which is an active ingredient in the United States Food and Drug Administration inhaled products, such as SEREVENT DISKUS, ADVAIR HFA and ADVAIR DISKUS. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.
Industry, Sector and Symbol
Trailing P/E Ratio-2.78260869565217
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$0.86 per share
Price / Book2.23
Return on Equity-119.00%
Return on Assets-101.14%
Neothetics (NASDAQ:NEOT) Frequently Asked Questions
What is Neothetics' stock symbol?
Neothetics trades on the NASDAQ under the ticker symbol "NEOT."
How were Neothetics' earnings last quarter?
Neothetics Inc (NASDAQ:NEOT) issued its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.13) EPS for the quarter. View Neothetics' Earnings History.
When will Neothetics make its next earnings announcement?
Who are some of Neothetics' key competitors?
Some companies that are related to Neothetics include SCYNEXIS (SCYX), AzurRx BioPharma (AZRX), Evoke Pharma (EVOK), Apricus Biosciences (APRI), Concordia International (CXRX), IntelliPharmaCeutics Intl (IPCI), Pernix Therapeutics (PTX), Neuralstem (CUR), Eyegate Pharmaceuticals (EYEG), N4 Pharma (N4P), Cellectar Biosciences (CLRB), Immune Pharmaceuticals (IMNP), SLS International (SLS), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), Forest Laboratories (FRX), Hi-Tech Pharmacal (HITK) and Questcor Pharmaceuticals (QCOR).
Who are Neothetics' key executives?
Neothetics' management team includes the folowing people:
- Susan A. Knudson, Chief Financial Officer (Age 53)
- Maria Feldman, Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance (Age 52)
- Kim P Kamdar, Lead Independent Director (Age 49)
- Martha J. Demski, Independent Director (Age 64)
- Maxim Gorbachev, Independent Director (Age 41)
- Jeffrey M. Nugent, Independent Director (Age 70)
When did Neothetics IPO?
(NEOT) raised $60 million in an initial public offering on Thursday, November 20th 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Piper Jaffray and Guggenheim Securities served as the underwriters for the IPO and Needham & Company was co-manager.
How do I buy Neothetics stock?
Shares of Neothetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neothetics' stock price today?
One share of Neothetics stock can currently be purchased for approximately $1.92.
How big of a company is Neothetics?
Neothetics has a market capitalization of $26.58 million. The biotechnology company earns $-13,010,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. Neothetics employs 7 workers across the globe.
How can I contact Neothetics?
Neothetics' mailing address is 9171 Towne Centre Dr Ste 250, SAN DIEGO, CA 92122-1236, United States. The biotechnology company can be reached via phone at +1-858-7501008 or via email at [email protected]
MarketBeat Community Rating for Neothetics (NEOT)MarketBeat's community ratings are surveys of what our community members think about Neothetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Neothetics (NASDAQ:NEOT) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Neothetics (NASDAQ:NEOT) Earnings History and Estimates Chart
Neothetics (NASDAQ NEOT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Neothetics (NASDAQ:NEOT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Neothetics (NASDAQ:NEOT)
No dividend announcements for this company have been tracked by MarketBeat.com
Neothetics (NASDAQ NEOT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 39.20%
Institutional Ownership Percentage: 1.74%
Neothetics (NASDAQ NEOT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/30/2015||Alta Partners Viii, L.P.||Insider||Sell||797,987||$1.51||$1,204,960.37|| |
|12/29/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||493,654||$1.53||$755,290.62|| |
|12/28/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||54,333||$1.59||$86,389.47|| |
|12/17/2015||Kenneth W. Locke||Insider||Sell||598||$1.26||$753.48|| |
|12/17/2015||Susan A. Knudson||CFO||Sell||1,005||$1.26||$1,266.30|| |
|12/15/2015||Alta Partners Viii, L.P.||Major Shareholder||Sell||529,261||$1.44||$762,135.84|| |
|11/18/2015||Kenneth W. Locke||insider||Sell||6,098||$8.30||$50,613.40||293|| |
|9/18/2015||Christopher Kemmerer||VP||Sell||1,000||$12.20||$12,200.00||10,848|| |
|9/1/2015||Susan A. Knudson||CFO||Sell||3,000||$11.33||$33,990.00||492|| |
|3/19/2015||George W Mahaffey||CEO||Buy||1,000||$7.76||$7,760.00|| |
|11/25/2014||Daniel Janney||Director||Sell||149,286||$14.00||$2,090,004.00|| |
|11/25/2014||Rmi Investments S.A.R.L.||Major Shareholder||Buy||70,000||$14.00||$980,000.00|| |
Neothetics (NASDAQ NEOT) News Headlines
|Evofem Announces Closing Of Merger With Neothetics|
finance.yahoo.com - January 17 at 5:32 PM
|Neothetics Announces Adjournment of Special Stockholders Meeting to Solicit Additional Votes for Merger With Evofem|
finance.yahoo.com - January 16 at 5:22 PM
|Pfenex (PFNX) Appoints Susan Knudson as CFO|
www.streetinsider.com - January 4 at 5:25 PM
|Should You Be Concerned About Neothetics Inc’s (NEOT) Risks?|
finance.yahoo.com - December 8 at 5:18 PM
|Who Are The Major Shareholders In Neothetics Inc (NEOT)?|
finance.yahoo.com - November 30 at 9:53 AM
|Neothetics, Inc. (NEOT) Short Interest Down 53.7% in November|
www.americanbankingnews.com - November 29 at 1:34 AM
|Neothetics, Inc. (NEOT) Issues Quarterly Earnings Results|
www.americanbankingnews.com - November 10 at 7:09 PM
|Neothetics Provides Business Update and Reports Third Quarter 2017 Financial Results|
globenewswire.com - November 9 at 7:44 AM
|Neothetics, Inc. (NEOT) Set to Announce Earnings on Wednesday|
www.americanbankingnews.com - November 1 at 4:28 AM
|Neothetics, How Will EvoFem Merger Impact Shareholders|
finance.yahoo.com - October 25 at 8:04 AM
|Have Investors Already Priced In Healthcare Growth For Neothetics Inc (NEOT)?|
finance.yahoo.com - October 24 at 7:34 AM
|Neothetics (NEOT) to Merge with Evofem Biosciences|
www.streetinsider.com - October 19 at 6:44 AM
|BRIEF-Neothetics Inc and Evofem Biosciences Inc announce merger agreement to create Women’S health company|
www.reuters.com - October 19 at 6:44 AM
|Neothetics's stock rockets on heavy volume after merger deal|
finance.yahoo.com - October 18 at 7:30 AM
|ValuEngine Upgrades Neothetics, Inc. (NEOT) to "Sell"|
www.americanbankingnews.com - October 17 at 11:38 PM
|Neothetics, Inc. (NEOT) Short Interest Update|
www.americanbankingnews.com - October 14 at 1:40 AM
|Biotech Stocks on Investors' Radar -- Neothetics, Pieris Pharma, and Repros Therapeutics|
www.marketwatch.com - September 28 at 12:43 PM
|Neothetics Inc (NEOT): How Does It Impact Your Portfolio?|
finance.yahoo.com - September 19 at 2:38 AM
|Short Interest in Neothetics, Inc. (NEOT) Increases By 48.6%|
www.americanbankingnews.com - August 28 at 1:20 AM
|BRIEF-Neothetics posts Q2 loss per share $0.20|
www.reuters.com - August 12 at 8:14 PM
|Neothetics, Inc. (NEOT) Releases Earnings Results, Meets Estimates|
www.americanbankingnews.com - August 11 at 7:54 PM
|Neothetics Provides Business Update and Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 11 at 6:53 AM
|Neothetics Announces Review of Strategic Alternatives|
finance.yahoo.com - July 11 at 3:27 AM
|Neothetics stock plummets 66% on news of negative results for fat-reduction drug|
www.marketwatch.com - June 27 at 6:53 PM
|Neothetics Inc. (NEOT) Sank To A 10-Month Low After Phase 2 Study Failed|
www.rttnews.com - June 27 at 6:53 PM
|NEOTHETICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits|
biz.yahoo.com - April 3 at 6:07 PM
|Q4 2016 Neothetics Inc Earnings Release - Before Market Open|
us.rd.yahoo.com - March 23 at 7:18 PM
|Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results|
us.rd.yahoo.com - March 23 at 7:18 PM
|NEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - March 7 at 6:37 PM
|Form SC 13G/A Neothetics, Inc. Filed by: DRILL CRAIG A|
www.streetinsider.com - January 6 at 7:29 PM
|Neothetics (NEOT) Begins Phase II Study on Lead Candidate|
www.zacks.com - December 28 at 10:05 AM
|Neothetics (NEOT) Phase 2 Proof of Concept Trial for LIPO-202 Initiated for Double Chin|
www.streetinsider.com - December 24 at 6:18 PM
|Neothetics (NEOT) Leaped as New Drug Trial Commences|
www.baystreet.ca - December 23 at 8:17 PM
|NEOTHETICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement|
biz.yahoo.com - September 23 at 5:55 PM
|Neothetics Provides Business Update and Reports Second Quarter 2016 Financial Results|
www.nasdaq.com - August 11 at 9:37 AM
|NEOTHETICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders|
biz.yahoo.com - June 17 at 8:01 AM
|NEOTHETICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;|
biz.yahoo.com - June 6 at 8:01 AM
|NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits|
biz.yahoo.com - May 12 at 8:01 AM
|Q1 2016 Neothetics Inc Earnings Release - Before Market Open|
biz.yahoo.com - May 12 at 7:07 AM
|NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal|
biz.yahoo.com - February 18 at 4:08 PM
|Why Neothetics Is Getting Destroyed|
247wallst.com - December 15 at 1:15 PM
|NEOTHETICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - December 14 at 5:02 PM
|NEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events|
biz.yahoo.com - December 10 at 4:39 PM
|NEOTHETICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits|
biz.yahoo.com - December 1 at 5:21 PM
Neothetics (NASDAQ:NEOT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Neothetics (NASDAQ:NEOT) Income Statement, Balance Sheet and Cash Flow Statement
Neothetics (NASDAQ NEOT) Stock Chart for Thursday, January, 18, 2018